Sources | Names Used |
---|---|
CTRPv2 | doxorubicin:navitoclax (2:1 mol/mol) |
PharmacoGx | doxorubicin:navitoclax (2:1 mol/mol) |
Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | ZCCHC3 | CTRPv2 | pan-cancer | AAC | 0.17 | 5e-06 |
mRNA | BORCS7-ASMT | CTRPv2 | pan-cancer | AAC | 0.15 | 5e-06 |
mRNA | WDR7 | CTRPv2 | pan-cancer | AAC | 0.16 | 5e-06 |
mRNA | FBXL19 | CTRPv2 | pan-cancer | AAC | 0.15 | 5e-06 |
mRNA | KRBA2 | CTRPv2 | pan-cancer | AAC | 0.15 | 5e-06 |
mRNA | SRSF11 | CTRPv2 | pan-cancer | AAC | 0.15 | 5e-06 |
mRNA | DAND5 | CTRPv2 | pan-cancer | AAC | 0.15 | 5e-06 |
mRNA | APAF1 | CTRPv2 | pan-cancer | AAC | 0.15 | 6e-06 |
mRNA | ATP2B3 | CTRPv2 | pan-cancer | AAC | 0.15 | 6e-06 |
mRNA | VIMP | CTRPv2 | pan-cancer | AAC | -0.15 | 6e-06 |